L-Citrulline and Endothelial Function

Aging Clinical Trial

Official title:

Effect of Oral L-Citrulline on the Peripheral and Central Endothelial Function in Young and Older Adults

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05722860
• Other study ID #: 15485
• Status: Recruiting
• Phase: Phase 1
• Start date: January 3, 2024
• Est. completion date: December 28, 2024

Study information

• Verified date: February 2024
• Source: University of Oklahoma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The effect of L-Citrulline is well studied in relation to muscle strength, exhaustion, exercise performance, and endothelial function in health and disease. This study will extend current body of knowledge and will investigate the effect of L-Citrulline on brain vascular function.

Description:

Endothelial function is associated with nitric oxide (NO) availability for vasodilation, blood pressure and blood flow regulation, and vascular health. A large body of evidence demonstrates that aging is associated with a decrease in bioavailability of NO, with more pronounced decrease in sedentary individuals. NO can be produced via the NO synthase (NOS) enzymes, which catalyze the conversion of L-Arginine - a semi-essential amino acid found in fish, nuts and legumes amongst others - to L-Citrulline and produce NO as an endproduct. While the effect of L-Citrulline is extensively studied in relation to muscle strength, exhaustion, exercise performance, as well as on endothelial function in healthy and diseased individuals (including obese and those with heart failure), the effect of L-Citrulline on brain vascular function is not well studied.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 28, 2024
• Est. primary completion date: July 3, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Age 21-45 and =55-90 years of age

• Adequate hearing and visual acuity to participate in the examinations

• Ability to read and write in English

• Competence to provide informed consent

Exclusion Criteria:

• Active CNS disease including multiple sclerosis, uncontrolled seizures, active brain cancer

• Cerebrovascular accident other than TIA within 60 days prior to Visit 0

• Major psychiatric disease, including major depression not currently controlled on medications, alcohol or drug abuse

• Treatment with other Citrulline enhancers (L-Arginine, L-Citrulline Malate) within 4 weeks prior to Visit 0

• Any other medical condition which, in the opinion of investigator, would render the patient inappropriate or too unstable to complete the study protocol

Related Conditions & MeSH terms

• Aging

Intervention

Drug:
• L-Citrulline, capsule
5g/daily dose for the duration of 1 week intervention

Locations

Country	Name	City	State
United States	Andriy Yabluchanskiy	Oklahoma City	Oklahoma

Sponsors (1)

Lead Sponsor	Collaborator
University of Oklahoma

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in neurovascular coupling using functional near infrared spectroscopy (fNIRS)	Functional near infrared spectroscopy (fNIRS) will be performed during the cognitive n-back task. fNIRS approach generates data that represent a relative change in oxygenated and deoxygenated hemoglobin measured over the cortical brain tissues. Neurovascular coupling will be evaluated as a change in oxy- and deoxy-hemoglobin between before and after treatment. Units of measure - beta. Reported as a %change from baseline, before and after treatment.	1 week
Primary	Change in neurovascular coupling using the dynamic retinal vessel analysis	Flicker light-induced dilation of the retinal vessels (percentage increase over baseline diameter) will be measured in the right or left eye of each study participant using the Dynamic Vessel Analyzer (DVA, IMEDOS Systems, Jena, Germany). Units of measure mm, reported as a %change from baseline, before and after treatment.	1 week
Primary	Change in neuronal activity	EEG signal will be collected to generate spectral data. These data will be used for comparison of EEG activity between before and after treatment. Units of measure - power spectral density. Reported as a %change from baseline, before and after treatment.	1 week
Secondary	Change in microvascular endothelial function	Changes in microvascular endothelial function will be assessed using laser speckle contrast imaging (LSCI) in the hand using the flow mediated dilation approach. The change in skin perfusion is calculated and reported as a %change from baseline, between before and after treatment. Units of measure - perfusion index (arbitrary units). Reported as a %change from baseline, before and after treatment.	1 week
Secondary	Change in macrovascular endothelial function	Changes in macrovascular endothelial function will be assessed using sonography during flow mediated dilation approach. The change in brachial artery diameter (mm) is calculated and reported as a %change from baseline, between before and after treatment.	1 week
Secondary	Change in Glycocalyx - perfused boundary region	Video recordings of the sublingual vasculature will be performed using the high definition video camera GlycoCheck (Microvascular health solutions). Data collected will include perfused boundary region (um), and will be used for comparison before and after treatment.	1 week
Secondary	Change in capillary density	Video recordings of the sublingual vasculature will be performed using the high definition video camera GlycoCheck (Microvascular health solutions). Data collected will include capillary density (mm/mm^2), and will be used for comparison before and after treatment.	1 week
Secondary	Change in red blood cell velocity	Video recordings of the sublingual vasculature will be performed using the high definition video camera GlycoCheck (Microvascular health solutions). Data collected will include red blood cell velocity (um/sec), and will be used for comparison before and after treatment.	1 week
Secondary	Change in grip strength	The change in hand grip strength will be measured before and after intervention. Data collected will include measurements of power in kg for left and right hand respectively	1 week
Secondary	Change in Attention	CANTAB research attention test.Reported as a %change from baseline, before and after treatment.	1 week
Secondary	Change in Working Memory	CANTAB research working memory test.Reported as a %change from baseline, before and after treatment.	1 week
Secondary	Change in Executive Function	CANTAB research executive function test.Reported as a %change from baseline, before and after treatment.	1 week
Secondary	Change in Processing Speed	CANTAB research processing speed test.Reported as a %change from baseline, before and after treatment.	1 week
Secondary	Blood collection	Blood samples will be collected to measure L-Citrullin related metabolites.	1 week